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ABSTRACT
Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the
bloodstream originating from both non-tumor- and tumor-derived cells. A previous
study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer
patients compared to controls. Tumor suppressor gene products including BRCA1 and
BRCA2 (BRCA1&2) play an important role in telomere maintenance. In this study, we
hypothesized that the plasma telomeric cfDNA level is associated with the mutation
status of BRCA1&2 genes. To test this hypothesis, we performed plasma telomeric
cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the
BRCA1&2 mutation with age-matched controls of 28 healthy women. The results
showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1&2
mutation carriers than in age-matched controls from non-obese women (BMI < 30),
while there was no association between unaffected BRCA1&2 mutation carriers and
age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric
cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These
findings suggest that circulating cfDNA may detect dysfunctional telomeres derived
from cells with BRCA1&2 mutations and, therefore, its level is associated with breast
cancer susceptibility. This pilot study warrants further investigation to elucidate the
implication of plasma telomeric cfDNA levels in relation to cancer and obesity.

INTRODUCTION

the assays require prior information on specific genetic
or epigenetic alterations present in the original tumor
lesion. In order to detect cfDNA alterations associated
with breast cancer initiation (where the amount of affected
DNA is significantly low), the assays require sufficient
improvement in the sensitivity of the assay, making this
research area quite challenging [3, 4].
We recently devised a qPCR-based cfDNA assay to
measure telomeric cfDNA levels (i.e., relative amounts
of [TTAGGG]n sequences) in plasma. Using this assay,
we reported that plasma telomeric cfDNA levels were
significantly decreased in sporadic breast cancer patients

Plasma, serum, and other biofluids contain very
low amounts of circulating extracellular cell-free DNA,
also called cfDNA. cfDNA has become an increasingly
important source for the development of liquid biopsy
assays for early cancer detection. Indeed, it has been
shown that cancer patients present both normal tissueand tumor-derived cfDNA in the bloodstream [1]. Current
cfDNA assays have mostly focused on monitoring
cancer-specific mutations or methylation changes by
targeting cell-free tumor DNA (ctDNA) [2]. In this case,
www.impactjournals.com/oncotarget
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with no prior treatment, compared to non-cancer controls
[5]. While a plasma centromeric cfDNA level was
also measured in the study and the difference between
breast cancer patients and controls was also statistically
significant, the actual effect size was modest between
breast cancer patients and controls [5]. These results
indicate that changes in telomeric cfDNA levels could
be more constructive as a biomarker than changes in
centromeric cfDNA levels during breast carcinogenesis.
Furthermore, we found that the plasma telomeric cfDNA
level in women with advanced breast tumors (stages II–III)
was lower than those at earlier stages of breast cancer
(stages 0–I) [5]. These findings suggest that telomere
dysfunction (e.g., rapid telomere shortening) in body
tissues might accumulate during cancer development
and be associated with cancer progression, resulting in
dynamic changes in the plasma telomeric cfDNA level.
Two major factors responsible for telomere length
shortening are cellular replicative aging and genetics.
BRCA1 and BRCA2 (BRCA1&2) are multifunctional
proteins and maintain genomic stability by regulating
DNA repair, transcription, and cell cycle in response
to DNA damage [6, 7]. Several studies suggest that
BRCA1&2 haploinsufficiency could involve defects in
telomere maintenance [8–10]. Because BRCA1&2 gene
mutation carriers have a high risk of developing earlyonset breast and ovarian cancer during their lifetime, the
aim of this study is to determine whether plasma telomeric
cfDNA level is associated with the BRCA1&2 mutations.
This pilot study provides important supportive evidence
for ensuring further research to determine the potential
value of the plasma telomeric cfDNA level in predicting
cancer development and cancer risk.

eliminating the confounding factor of age. Overall, there
was no difference of the telomeric cfDNA level between
BRCA1&2 carriers and controls (p = 0.0774, d = 0.351).
However, upon subgrouping the samples by BMI, the
plasma telomeric cfDNA level was significantly lower in
BRCA1&2 carriers than those in age-matched controls in
the non-obese group (n = 14 pairs, p = 0.0253, d = 0.691)
(Figure 1A). In contrast, there was no difference in the
telomeric cfDNA level between BRCA1&2 carriers and
age-matched controls in the obese group (n = 14 pairs,
p = 0.8991, d = 0.036) (Figure 1B). Wilcoxon signed-rank
test showed that the p-value was also significant when
BRCA1&2 carriers were compared with age-matched
controls in the non-obese group (p = 0.0257), while the
p-value was 0.976 in the obese group (Figure 1B). The
effect size (difference) between BRCA1&2 carriers and
age-matched controls in the non-obese group was a range
from medium to large (d = 0.691). We also measured
relative telomere length by qPCR in matched peripheral
blood DNA samples as several reports have shown
BRCA1&2 carriers having relatively shorter telomeres in
leukocytes as compared to healthy controls [10, 11]. Our
analyses using paired t-test showed that leukocyte telomere
length was significantly shorter in BRCA1&2 carriers
than those in age-matched controls in the non-obese group
(p = 0.0320, d = 0.666) but not in the obese group (p = 0.8203,
d = 0.064) (Figure 1C and 1D). However, there was no
association between the plasma telomeric cfDNA level (T/L
copy ratio) and leukocyte telomere length (T/S ratio) in this
study population (Supplementary Figure 1), supporting our
previous findings that leukocyte DNA is not a major source
of cfDNA production [5].
To further evaluate our results with other method,
we used the Tyrer-Cuzick model that is a well-studied,
widely available model for predicting breast cancer risk
[12, 13]. We hypothesized that either telomeric cfDNA
level or telomere length or both fit with the Tyrer-Cuzick
model in non-obese women, thus acting as potential
biomarker(s) for breast cancer development. When
individual risk of developing breast cancer within 10 years
was calculated and the plasma telomeric cfDNA level
was compared with the 10-year risk, we found that the
telomeric cfDNA level was inversely correlated with the
10-year risk (p = 0.00675, r2 = 0.2007), while the telomere
length results were not significantly correlated with the
10-year risk (p = 0.1363, r2 = 0.0083) (Figure 2). Only
when the data was analyzed in the non-obese controls
(the 10-year risk < 5%, n = 22), the telomere length
results were correlated with the 10-year risk (p = 0.0161,
r2 = 0.2565). This significant correlation is likely attributed
to age because the age factor is strongly associated with
the 10-year risk score especially when the risk is less than
5% (Supplementary Figure 2).
Our findings indicate that obesity might have an effect
on plasma telomere cfDNA level or/and leukocyte telomere
length. Therefore, we next compared the difference in the

RESULTS
We hypothesized that a circulating telomeric cfDNA
level could be affected by BRCA1&2 heterozygous
mutations; consequently, the telomeric cfDNA level
decreases in BRCA1&2 mutation carriers as compared
to healthy controls. In order to avoid reverse causation,
we tested this hypothesis only in unaffected women. We
analyzed plasma samples from 56 individuals, including
28 unaffected women carrying either a BRCA1 mutation
(n = 16), a BRCA2 mutation (n = 9), or both BRCA1 and
BRCA2 mutations (n = 3), and 28 age-matched healthy
controls. The age range was from 23 to 74. Demographic
and clinical characteristics of both cases and controls
are provided in Table 1 and Supplementary Table 1,
respectively. Telomeric cfDNA qPCR assay was performed
as previously described with minor modifications [5].
Both parametric and non-parametric tests were employed
to compare the telomeric cfDNA qPCR results collected
from the two groups (carriers and controls). We first
used paired t-test to compare the results between agematched BRCA1&2 carriers vs. control women, thereby
www.impactjournals.com/oncotarget
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Table 1: Demographic and clinical characteristics, telomeric cfDNA level, and telomere length of BRCA1&2 carrier
women
Age

Race

BMI

Current
smoking
status

Menstrual
Status

BR02-469

23

White

27.3

No

Pre

BRCA1

BR27-689

23

White

32.1

No

Pre

BR12-497

24

White

28.5

No

Pre

BR31-071

24

White

24.3

No

BR03-560

29

White

27.3

No

BR05-977

32

White

26.2

BR24-030

34

White

32.0

Sample ID

Telomeric
cfDNA level
(± S.E.)

Relative
telomere length
(± S.E.)

4.9%

0.176 (± 0.0039)

1.97 (± 0.080)

BRCA2

5.7%

0.169 (± 0.0044)

2.39 (± 0.093)

BRCA1

8.6%

0.114 (± 0.0071)

1.70 (± 0.104)

Pre

BRCA1

19.0%

0.131 (±0.0009)

2.14 (± 0.084)

Pre

BRCA1

26.3%

0.146 (± 0.0079)

1.60 (± 0.095)

No

Pre

BRCA2

19.4%

0.247 (± 0.0621)

0.97 (± 0.054)

No

Pre

BRCA1

66.7%

0.038 (±0.0055)

2.00 (± 0.167)

18.8%

0.079 (± 0.0064)

1.70 (± 0.049)

Mutation 10-year
Status
risk

BR07-177

37

White

33.9

No

Post

BRCA1 &
BRCA2

BR34-032

37

White

21.1

No

Pre

BRCA2

16.1%

0.154 (± 0.0067)

2.08 (± 0.151)

BR11-468

38

White

27.3

Yes

Pre

BRCA1

23.8%

0.158 (± 0.0077)

2.24 (± 0.130)

BR14-590

39

White

32.8

No

Pre

BRCA2

18.8%

0.105 (± 0.0091)

1.87 (± 0.136)

BR35-034

41

White

31.6

No

pre

BRCA1

30.1%

0.159 (± 0.0079)

2.33 (± 0.070)

BR06-978

42

White

19.1

No

Post

BRCA2

17.2%

0.042 (± 0.0050)

1.76 (± 0.032)

BR13-588

45

White

31.2

No

Post

BRCA2

22.8%

0.090 (± 0.0071)

1.79 (± 0.067)

BR26-158

45

White

39.4

No

n/a

BRCA1

33.7%

0.214 (± 0.0175)

1.61 (± 0.093)

BR01-938

46

White

22.7

No

Post

BRCA1

32.8%

0.074 (± 0.0048)

1.76 (± 0.110)

BR28-925

46

White

32.1

No

Pre

BRCA2

21.5%

0.147 (± 0.0046)

1.48 (± 0.059)

BR16-766

47

White

35.7

No

Post

BRCA1

34.9%

0.171 (± 0.0185)

1.54 (± 0.110)

BR20-204

48

White

25.8

No

Post

BRCA1

19.9%

0.080 (± 0.0032)

2.14 (± 0.121)

BR32-664

49

White

32.6

No

Post

BRCA1

28.4%

0.126 (± 0.0026)

2.00 (± 0.068)

BR04-976

50

White

26.6

No

Pre

BRCA2

22.8%

0.131 (± 0.0074)

0.81 (± 0.022)

BR30-175

51

White

35.4

No

Post

BRCA1

26.3%

0.090 (± 0.0029)

1.39 (± 0.036)

BR29-168

53

White

32.2

No

Post

BRCA1

26.9%

0.142 (± 0.0086)

1.59 (± 0.039)

28.2%

0.108 (± 0.0063)

1.47 (± 0.111)

BR36-383

56

White

29.3

No

Post

BRCA1 &
BRCA2

BR19-102

61

White

37.3

No

Post

BRCA1 &
BRCA2

27.9%

0.025 (± 0.0014)

1.46 (± 0.061)

BR33-750

66

White

27.1

No

Post

BRCA1

12.6%

0.195 (± 0.0054)

1.57 (± 0.152)

BR21-207

70

White

22.6

No

Post

BRCA2

29.5%

0.133 (± 0.0163)

1.65 (± 0.142)

BR17-822

74

White

33.5

No

Post

BRCA1

8.5%

0.060 (± 0.0071)

1.58 (± 0.065)

S.E., standard error of the mean.

*

DISCUSSION

plasma telomeric cfDNA level among 19 age-matched low
(< 30) and high (> 30) BMI healthy control pairs. Nonparametric Wilcoxon signed-rank test was employed and
showed that a lower plasma telomeric cfDNA level was
associated with obesity (BMI > 30) in healthy individuals
(p = 0.00034, d = 1.0667) (Figure 3A, Supplementary Table 2).
In contrast, we did not find the difference in leukocyte
telomere length between the obese and the non-obese
groups (p = 0.093, d = 0.421) (Figure 3B, Supplementary
Table 2), suggesting that obesity (based on BMI) is not a
strong modifier of telomere length [14, 15].
www.impactjournals.com/oncotarget

This pilot study is the first to determine the
association of the plasma telomeric cfDNA level with
genetic risk in unaffected women with and without
mutations in BRCA1 or/and BRCA2 genes. The findings
suggest that circulating plasma telomeric cfDNA levels
are affected by BRCA1&2 heterozygous mutations in nonobese women. Until now, conflicting studies report the
correlation between shorter telomere length in leukocytederived DNA and BRCA1&2 mutation status. Our results
4216
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Figure 1: Non-obese women with BRCA1&2 gene mutation have a lower plasma telomeric cfDNA level and shorter
leukocyte telomere length. (A) The telomeric cfDNA level was plotted using 14 age-matched pairs from non-obese women (BMI < 30).
Mean (± S.D.) of the telomeric cfDNA level was 0.191 (± 0.073) in controls and 0.135 (± 0.050) in BRCA1&2 carriers. 71.4% (10 of
14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2 carries. (B) The telomeric cfDNA level was plotted using 14 agematched pairs from obese women (BMI > 30). Mean (± S.D.) of the telomeric cfDNA level was 0.115 (± 0.040) in controls and 0.113
(± 0.053) in BRCA1&2 carriers. 50.0% (7 of 14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2 carries. (C) Relative
telomere length was plotted using the same pairs from non-obese in (A). Mean (± S.D.) of telomeric cfDNA level was 1.85 (± 0.45) in
controls and 1.69 (± 0.41) in BRCA1&2 carriers. 71.4% (10 of 14 pairs) show a reduction in the telomeric cfDNA level in BRCA1&2
carries. (D) Relative telomere length was plotted using the same pairs from obese women in (B). Mean (± S.D.) of telomeric cfDNA level
was 1.79 (± 0.37) in controls and 1.77 (± 0.30) in BRCA1&2 carriers. 64.2% (9 of 14 pairs) show a reduction in the telomeric cfDNA level
in BRCA1&2 carries. All p values were shown based on paired Student’s t test.
www.impactjournals.com/oncotarget
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confirmed that leukocyte telomere length was affected by
BRCA1&2 heterozygous mutations in non-obese women
(but not in obese women). Furthermore, it is noteworthy
that there is a significant correlation between the telomeric
cfDNA level and the Tyrer-Cuzick 10-year risk score of
developing breast cancer. These findings support our
hypothesis that the telomeric cfDNA level could be a
biologically-relevant quantitative biomarker for breast
cancer development.
Although the underlying molecular mechanism of
alteration in the plasma telomeric cfDNA level remains
unclear, several studies reported that epithelial breast cells

possess enhanced proliferative potential in women with
BRCA1&2 haploinsufficiency [16–18]. We speculate
that after the occurrence of “one-hit” of BRCA1&2 gene,
the remaining wild-type allele of BRCA1&2 may not be
sufficient to recover the deficiency in DNA repair and/
or replication properly at the telomeres in target somatic
tissues. Consequently, a telomere shortening rate in
cells of BRCA1&2 carriers could be accelerated during
development and aging, compared to controls [19].
Thus, we speculate that the circulating telomeric cfDNA
level could reflect the somatic and dynamic changes in
telomere dysfunction in target tissue cells; as a result, we

Figure 2: The plasma telomeric cfDNA level is correlated with individual 10-year breast cancer risk in non-obese
women. (A) Comparison between the plasma telomeric cfDNA level and the 10-year risk in non-obese women (n = 28). (B) Comparison
between relative leukocyte telomere length and the 10-year risk in non-obese women (n = 28).
www.impactjournals.com/oncotarget
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observed that BRCA1&2 carriers have relatively lower
telomeric cfDNA level than controls, even before a total
loss of the remaining wild-type allele occurs and cancer
appears. Moreover, we demonstrated that a lower plasma
telomeric cfDNA level was associated with a higher BMI.
The question of why the plasma telomeric cfDNA level
is lower in obese women requires further investigation;
however, we pose the following two possible explanations.
First, adipocyte cells may have relatively shorter telomeres
[20], and therefore increased death of the adipocyte cells
results in a lower telomeric cfDNA level in plasma.
Alternatively, obesity-related metabolic changes may
induce higher enzymatic activity (e.g., nuclease) in the
bloodstream that in turn facilitate degradation of cfDNA
fragments outside-in [21]. Therefore, it is of value to
further studying the implications of plasma telomeric
cfDNA levels in cancer development and obesity.
Because we only included Caucasian women, these
findings may not be generalized to men and/or other
ethnicities. In addition, because the sample size in this
study was limited, we were not able to identify differences
in the plasma telomeric cfDNA level between BRCA1
carriers, BRCA2 carriers, and dual carriers. This study
also lacks information about the specific mutation site(s)
on BRCA1&2 genes. Investigating the correlation of the

changes in the plasma telomeric cfDNA level with specific
BRCA1&2 mutation sites may provide new insights into
risk assessments of breast cancer.
In summary, we found that BRCA1&2 heterozygous
mutations altered the plasma telomeric cfDNA level in
non-obese women. This work highlights that the plasma
telomeric cfDNA level may reflect the dynamic changes
occurring in the telomeres of the somatic tissue cells
as a result of genetic predisposition (i.e., BRCA1&2
mutations). The next steps would be to replicate the
findings in a larger study. It is also critical to examine the
prospective associations between the plasma telomeric
cfDNA level, predictive risk factors for breast cancer, and
breast cancer occurrence, and also to further determine
whether the plasma telomeric cfDNA level mediates the
association between these risk factors and breast cancer.

MATERIALS AND METHODS
Human specimens
Paired leukocyte DNA and frozen plasma samples
were collected from BRCA1&2 mutation carriers
(n = 28, 23 ≤ age ≤ 74, mean age = 46) and their agematched controls (n = 28, ± 1 year) by the Susan G. Komen

Figure 3: Healthy obese women have a lower telomeric cfDNA level than healthy non-obese women. (A) The telomeric
cfDNA level was sub-grouped by BMI using age-matched control women (n = 19 pairs). Mean (± S.D.) of the telomeric cfDNA level was
0.217 (± 0.084) in the BMI < 30 group and 0.105 (± 0.046) in the BMI > 30 group. 84.2% (16 of 19 pairs) show a reduction in the telomeric
cfDNA level in the BMI > 30 group. (B) Relative telomere length was sub-grouped by BMI using age-matched control women (n = 19
pairs). Mean (± S.D.) of telomere length was 1.67 (± 0.35) in the BMI < 30 group and 1.83 (± 0.34) in the BMI > 30 group. There is no
difference of telomere length between two groups. All p values were shown based on Wilcoxon signed-rank test.
www.impactjournals.com/oncotarget
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Tissue Bank at Indiana University Simon Cancer Center
(KTB) with an approved Indiana University Institutional
Review Board protocol. All samples were collected in
accordance with standard operating procedures described
on the KTB website and with donor’s written informed
consent. All BRCA1&2 carrier cases and healthy
controls were unaffected women. Of note, the BRCA1&2
mutation status of controls was based on self-reported
information. The demographical and clinical information
of the study subjects were collected by the KTB through
a baseline questionnaire, and were shown in Table 1 and
Supplementary Table 1. Body Mass Index (BMI) was
calculated as weight divided by squared height.

Line copy number) calculated from the average of more
than three independent experiments.

Leukocyte DNA extraction
Paired leukocyte DNAs along with plasma
from both case and control women were obtained as a
lyophilized power after the Komen Tissue Bank was
extracted from whole blood samples using the Flex Star
automated system with the AGFStar Fresh WB Extraction
Kit (Autogen). The DNA was rehydrated with UltraPure
DNase/RNase-free water (Thermo Fisher Scientific,
10977015). The DNA concentration was quantitated
by Nanodrop 2000 spectrophotometer (Thermo Fisher
Scientific).

Plasma cfDNA extraction

Relative telomere length measurement

Frozen plasma samples were thawed on ice prior to
cfDNA isolation and centrifuged for 3 min at ≥ 11,000 × g
in order to remove residual cells, cell debris, and particulate
matter. A sodium Iodide (NaI)-based method was used
for each cfDNA extraction as described previously [5].
cfDNA concentrations were measured using Quant-iT™
PicoGreen™ dsDNA Reagent (Thermo Fisher Scientific).
The fluorescence intensity was measured with a Synergy 2
Multi-Mode Reader at emission wavelength of 520 nm and
excitation wavelength of 480 nm.

Singleplex telomere length qPCR was performed
with a QuantStudio 6 Flex Real-Time PCR System and
analyzed as described previously [5, 22, 23]. The qPCR
was performed on QuantStudio 6 Flex Real-Time PCR
System (Thermo Fisher Scientific) in 10 μL volume of
PCR reaction with 1× SYBR Select (Thermo Fisher
Scientific), primers, and DNA as template. The telomere
primers (telg and telc) and β-globin gene primers (hbgu
and hbgd) were used for this assay. Each DNA standard
curve was generated using a pooled female genomic DNA
(Promega, G152A) and used for calculation of the T/S
ratios (= ratios of “telomere quantities/single copy gene
quantities”). All experimental DNA samples were repeated
at least three times in duplicate. All replicate samples had
a standard deviation of less than 0.5 for the threshold cycle
(Ct) values.

Telomeric cfDNA qPCR assay
Telomeric cfDNA levels were measured by qPCR as
described previously except for some minor modifications
[5]. The qPCR was performed on QuantStudio 6 Flex
Real-Time PCR System (Thermo Fisher Scientific) in
10 μL volume of PCR reaction with 1× SYBR Select
(Thermo Fisher Scientific), primers, and cfDNA (~50 pg)
as template. The primer sequences are shown in
Supplementary Table 3. The thermal cycling profile is
Stage 1 for 2 min at 95°C; Stage 2 for 2 cycles of 15 s at
94°C, 15 s at 49°C; and Stage 3 for 40 cycles of 15 s at
94°C, 15 s at 60°C, 20 s at 72°C. The qPCR results were
analyzed based on plasmid DNA standard curves. The
plasmid DNA contains (TTAGGG)13 and 121 bp of LINE
(Long INterspersed Element) nucleotide sequences. Five
concentrations of a plasmid DNA sample were prepared
by five serial dilutions (3.62 × 109 to 5.79 × 106 copies).
To monitor and compensate for inter-plate variations in
PCR efficiency, each plate included standard plasmid
DNAs as well as reference DNA (Promega, G152A). All
experimental DNA samples were repeated at least three
times in duplicate. All samples have a standard deviation
of less than 0.5 for the threshold cycle (Ct) values. The
inter- and intra-assay coefficients of variations (CVs) were
13.0% and 3.9%, respectively. Melting curve analysis was
performed on every run to verify specificity and identity
of the PCR products. The telomeric cfDNA levels were
presented as T/L copy ratios (= telomere copy number/
www.impactjournals.com/oncotarget

Breast cancer risk assessment
The Tyrer-Cuzick (or International Breast
Intervention Study, IBIS) model was used to estimate a
woman’s risk of developing breast cancer within the next
10 years using information about BRCA1/2 mutation
carrier status and other risk factors including family
history of breast and ovarian cancer, age at menarche,
parity, age at first childbirth, age at menopause, atypical
hyperplasia, lobular carcinoma in situ, height, and body
mass index. The risk factors were entered into the model
using the freely available software IBIS_RiskEvaluator_
v8b (www.ems-trials.org/riskevaluator) [12, 13].

Statistical analysis
Shapiro-Wilk test was used to test for normality in
each group. Student’s t test (parametric) and Wilcoxon
signed-rank test (non-parametric) were performed to test
the association between a telomeric cfDNA level and
breast cancer risk factors (BRCA1&2 mutations, BMI).
Cohen’s d was used to calculate the effect size for paired
4220
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two-sample t test using WebPower (http://webpower.
psychstat.org) [24]. Linear regression analysis was used
to examine the correlation between the plasma telomeric
cfDNA level and leukocyte telomere length, as well as
between the 10-year risk and either the plasma telomeric
cfDNA level or leukocyte telomere length. R squared (r2)
was used for assessing the fit of the regression line. Twotailed p values of less than 0.05 were considered to be
statistically signiﬁcant.
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